Can Docebo Stock Turn a $6,000 TFSA Investment Into $60,000?

Docebo is a high-growth tech stock that can deliver outsized gains to investors. Let’s see if it should be part of your TFSA in 2022.

| More on:
A worker uses the cloud for paperless work. tech

Source: Getty Images

The Tax-Free Savings Account, or TFSA, is a registered account that is popular among Canadians. You can buy and hold a variety of qualified investments in the TFSA, such as bonds, stocks, and mutual funds.

Any income from the TFSA in the form of interests, dividends, or capital gains is exempt from Canada Revenue Agency taxes. So, the TFSA is ideal for those looking to own growth stocks and benefit from outsized gains over time.

Growth stocks generally grow at an enviable pace and outpace the broader markets in a bull run. But, due to their steep valuations, growth stocks also trail the market when sentiments turn bearish.

One such growth stock that can be part of your TFSA in 2022 is Docebo (TSX:DCBO)(NYSE:DCBO). Valued at a market cap of $1.3 billion. Docebo’s stock price is down 68% from all-time highs. Despite its massive pullback, Docebo has returned 137% to investors since its IPO in late 2019.

Let’s see if DCBO stock can turn a $6,000 TFSA investment into $60,000 by the end of this decade.

Is Docebo a good stock to buy?

Docebo was founded in 2005 and operates in the enterprise e-learning space. In recent years, corporate e-learning solutions have become part of the core strategy of many companies. Launched initially as an open-source model, Docebo transitioned to a subscription-based cloud platform in 2012.

It was among the first companies to introduce artificial intelligence and integrate it with e-learning to help companies gain a competitive advantage among peers.

Since 2018, Docebo has managed to increase revenue 3.8 times to US$104.2 million in 2021. The learning software maker ended the June quarter with 3,106 customers and US$138 million of annual recurring revenue. In fact, recurring revenue accounts for 91% of total sales. A subscription-based model allows companies to generate predictable cash flows across market cycles.

The company ended Q2 with a net dollar retention rate of 113%, indicating existing customers have increased spending on the Docebo platform by 13% in the last year.

Around 75% of Docebo’s customers are located in North America. So, the company has enough room to gain traction in other international markets. Some of Docebo’s big-ticket clients include Amazon Web Services, Thomson Reuters, and HP Inc.

The ongoing pandemic has acted as a tailwind for Docebo due to the shift towards remote work globally. Around 94% of learning and development professionals are looking to change their strategy in response to COVID-19.

Further, Docebo is part of a rapidly expanding addressable market that is forecast to touch US$29.9 billion in 2025, up from US$9.5 billion in 2019, indicating annual growth rates of 21% in this period.

The bear case for DCBO stock

Despite its stellar revenue growth over the years, Docebo continues to report an adjusted loss. Analysts forecast the company to narrow its losses from US$0.53 per share in 2021 to US$0.34 per share in 2022. Management expects to report break-even net income in 2023.

Docebo stock is valued at 9.7 times forward sales, which is quite steep for an unprofitable company. DCBO might move lower if the broader indices continue to lose momentum due to a challenging macro environment.

But Bay Street remains bullish on Docebo stock and expects it to more than double in the next 12 months. Docebo’s widening addressable market should drive its sales higher in the upcoming decade. In the case it improves profit margins and reports robust revenue growth in the future, Docebo can turn a $6,000 TFSA into $600,000 within the next 10 years.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Amazon, Docebo Inc., and HP. The Motley Fool has a disclosure policy.

More on Tech Stocks

Man data analyze
Tech Stocks

3 Reasons Celestica Stock Is a Screaming Buy Now

These three reasons make Celestica stock a screaming buy for long-term investors.

Read more »

profit rises over time
Dividend Stocks

These 2 Dow Stocks Are Set to Soar in 2025 and Beyond

Two Dow Jones stocks are screaming buys but Canadians must hold them in an RRSP or RRIF to avoid paying…

Read more »

telehealth stocks
Tech Stocks

Well Health Stock: Buy, Sell, or Hold?

Another record-breaking quarter and strong demand sets the stage for continued momentum for Well Health stock.

Read more »

3 colorful arrows racing straight up on a black background.
Dividend Stocks

TSX Stocks Soaring Higher With No Signs of Slowing

Three TSX stocks continue to beat the market and could soar higher in an improving investment landscape.

Read more »

profit rises over time
Tech Stocks

2 Non-AI Tech Stocks to Buy in November for Better Returns

Not all AI stocks are riding the hype train, and for many investors, well-understood and predictable growth stocks might be…

Read more »

worry concern
Tech Stocks

In a Few Years, You’ll Probably Regret Not Owning BlackBerry Stock

Here’s why I believe BlackBerry could be one of the most overlooked Canadian tech stocks right now.

Read more »

A worker uses a double monitor computer screen in an office.
Tech Stocks

Is Constellation Software Stock a Buy for its 0.25% Dividend Yield?

Here's what investors may want to consider when it comes to Dollarama (TSX:DOL) and its relatively low dividend yield.

Read more »

Nurse talks with a teenager about medication
Tech Stocks

Shares of WELL Health Just Zoomed. Is It a Buy?

Given its improving financials and healthy growth prospects, WELL Health could deliver superior returns over the next three years.

Read more »